FR1731M - Nouvel amino-pyrazole utilisable en thérapeutique, notamment comme médicament pour le traitement des affections inflammatoires. - Google Patents

Nouvel amino-pyrazole utilisable en thérapeutique, notamment comme médicament pour le traitement des affections inflammatoires.

Info

Publication number
FR1731M
FR1731M FR885433A FR885433A FR1731M FR 1731 M FR1731 M FR 1731M FR 885433 A FR885433 A FR 885433A FR 885433 A FR885433 A FR 885433A FR 1731 M FR1731 M FR 1731M
Authority
FR
France
Prior art keywords
pyrazole
therapy
drug
treatment
inflammatory conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR885433A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
BASF Schweiz AG
Original Assignee
Ciba Geigy AG
Ciba AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, Ciba AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of FR1731M publication Critical patent/FR1731M/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
FR885433A 1961-01-24 1962-01-22 Nouvel amino-pyrazole utilisable en thérapeutique, notamment comme médicament pour le traitement des affections inflammatoires. Expired FR1731M (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH77061A CH401071A (de) 1961-01-24 1961-01-24 Verfahren zur Herstellung neuer Aminopyrazole

Publications (1)

Publication Number Publication Date
FR1731M true FR1731M (fr) 1963-03-18

Family

ID=4194763

Family Applications (1)

Application Number Title Priority Date Filing Date
FR885433A Expired FR1731M (fr) 1961-01-24 1962-01-22 Nouvel amino-pyrazole utilisable en thérapeutique, notamment comme médicament pour le traitement des affections inflammatoires.

Country Status (4)

Country Link
CH (1) CH401071A (fr)
FR (1) FR1731M (fr)
MY (1) MY6600004A (fr)
NL (2) NL273881A (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906644A (en) * 1986-11-20 1990-03-06 Mitsubishi Kasei Corporation Lipid-peroxide formation inhibiting composition and novel compounds useful therefor

Also Published As

Publication number Publication date
NL273881A (fr)
NL127998C (fr)
CH401071A (de) 1965-10-31
MY6600004A (en) 1966-12-31

Similar Documents

Publication Publication Date Title
BE632037A (fr) Nouveau composé utilisable pour le traitement des manifestations inflammatoires ou douloureuses.
FR3639M (fr) Nouvelle protéine utilisable en thérapeutique, notamment comme agent pour le traitement de tumeurs solides.
FR1731M (fr) Nouvel amino-pyrazole utilisable en thérapeutique, notamment comme médicament pour le traitement des affections inflammatoires.
FR126M (fr) Nouveau médicament notamment pour le traitement de l'hyperlipémie post-prandiale ou chronique.
FR1856M (fr) Nouvel amino-pyrazole utilisable en thérapeutique, notamment comme médicament pour le traitement des affections inflammatoires.
FR1242M (fr) Médicament, utilisable notamment pour le traitement des affections fongiques, a base de dérivés de la griséofulvine.
FR1878M (fr) Nouveau polysaccharide, utilisable en thérapeutique, notamment pour le traitement des tumeurs solides.
FR2413M (fr) Nouveau médicament notamment pour le traitement des manifestations inflammatoires et douloureuses.
FR1204M (fr) Nouveau médicament, notamment pour le traitement de l'hyperlipémie chronique ou post-prandiale.
FR1729M (fr) Nouveau médicament notamment pour le traitement des manifestations inflammatoires et douloureuses.
FR1412M (fr) Nouveau médicament notamment pour le traitement des bronchites, pneumonies, collapsus cardiaques et défaillances cardiaques.
FR363M (fr) Nouveau médicament pour le traitement des trypanosomoses, des salmonelloses et des infections pénicillo-résistantes.
BE598672A (fr) Composition thérapeutique pour le traitement des affections hépatiques.
FR1783M (fr) Formes stabilisées des diméthylcarboxy-alkylsulfonium utilisées, notamment, pour le traitement des affections hépatiques et vasculaires.
FR1982M (fr) Nouvelles alcanamides-hydrazines n-substituées, utilisables notamment dans le traitement des infections staphylococciques rebelles.
BE630069A (fr) Composition thérapeutique pour le traitement du parkinsonisme.
FR2019M (fr) Nouveau thioéther utilisable en thérapeutique, notamment pour le traitement de diverses tumeurs solides.
FR28F (fr) Nouveau médicament notamment pour le traitement des manifestations inflammatoires et douloureuses.
FR3115M (fr) Nouveau médicament utilisable notamment pour le traitement des affections cardiovasculaires dégéneratives.
FR2148M (fr) Composition topique pour le traitement de verrues.
FR1611M (fr) Nouveau médicament, pour le traitement des congestions inflammatoires, en particulier des reins.
FR1920M (fr) Nouveau composé de la série de l'hydantoine utilisable notamment pour le traitement des salmonelloses.
FR1829M (fr) Nouveau médicament notamment pour le traitement des troubles de la coagulabilité sanguine.
FR1305M (fr) Nouveau médicament a usage externe notamment pour le traitement des affections dermatologiques.
FR1830M (fr) Nouveau médicament notamment pour le traitement de l'hyperactivité folliculo-stimulante.